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Background
The Task Force for the Management of Arterial Hypertension of the European Society 
of Hypertension (ESH) and of the European Society of Cardiology (ESC) published 
their ﬁ  rst European-speciﬁ  c guidelines in 2003. The decision to publish their own 
recommendations recognized that their historical endorsement of the World Health 
Organization (WHO) and International Society of Hypertension (ISH) guidelines, 
with some adaptation to the European situation, fell short of addressing the signiﬁ  cant 
differences in economic resources available, and diagnostic and therapeutic recom-
mendations between Europe and the rest of the world. The 2003 ESH/ESC Guidelines 
have since been revised and updated in light of changes in the ﬁ  eld and in the pursuit 
of good medicine and practice, and have recently been published in their second in-
carnation in the Journal of Hypertension (ESH/ESC Hypertension Practice Guidelines 
Committee 2003, 2007).
Despite the unequivocal cardiovascular (CV) risk conferred by high blood pres-
sure (BP), a signiﬁ  cant number of people with hypertension are unaware of their 
condition and target BP levels are seldom achieved (Burt et al 1995; Amar et al 2003; 
Mancia et al 2005). The 2007 ESH/ESC Guidelines emphasize the need to extend 
procedures for the effective capture, diagnosis and treatment of hypertension to a 
larger fraction of the clinical profession to beneﬁ  t a greater number of patients. The 
scope of the Guidelines covers: deﬁ  nition and classiﬁ  cation, diagnostic evaluation, 
therapeutic management and approach, treatment strategies, special conditions, 
associated risk factors, screening for secondary forms of hypertension, follow-up 
and implementation.
The aim of this supplement is to distil and summarize the key recommendations, 
with a particular emphasis on implications for practice from a primary care perspec-
tive. The recommendations are based on data from randomized clinical trials (RCTs) 
and observational studies as appropriate, and aim to facilitate decision-making and 
practice for all healthcare providers involved in the management of hypertension.
Deﬁ  nition
The WHO cites high BP as the leading cause of death worldwide (Erzzati et al 2002) 
because of its prevalence and its status as a signiﬁ  cant CV risk factor (Wolf-Maier 
et al 2003; Kearney et al 2005; Martiniuk et al 2007). The continuous relationship 
between both systolic and diastolic BP and CV morbidity and mortality (including 
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that relating to both coronary events and stroke) has been 
demonstrated in a number of observational studies and is 
continuous to systolic and diastolic levels of 115–110 mmHg 
and 75–70 mmHg, respectively (Joint National Committee 
on Detection, Evaluation and Treatment of High Blood Pres-
sure 1977, 1980; Collins et al 1990; MacHahom et al 1990; 
Prospective Studies Collaboration 2002). Furthermore, both 
systolic and diastolic BP are independently related to heart 
failure, peripheral artery disease (PAD) and end-stage renal 
disease (Criqui et al 1992; Kannel et al 1996; Klag et al 1996; 
Levy et al 1996).
For practical reasons, including their intrinsic use in key 
RCTs, classiﬁ  cation of hypertension and risk assessment 
should be based on systolic and diastolic BP. However, 
the Guidelines also recognize that pulse pressure may be a 
useful parameter to identify systolic hypertension in elderly 
patients who may be at particularly high risk (Blacher et al 
2000; Gasowski et al 2002; Laurent 2006). The Guidelines 
deﬁ  ne optimal BP as  120 (systolic) and  80 (diastolic), and 
normal BP as 120–129 (systolic) and/or 80–84 (diastolic). 
Figure 1 illustrates the classiﬁ  cation of hypertension, as re-
tained from the 2003 ESH/ESC Guidelines, with recognition 
that the threshold for hypertension should be regarded as 
ﬂ  exible; being higher or lower based on the total CV risk 
of each individual. It is of note, however, that if a patient’s 
systolic and diastolic pressures lie in different categories, the 
risk relating to the higher category should be attributed to the 
patient. Furthermore, low diastolic BP (eg, 60–70 mmHg) 
should be regarded as an additional risk. Isolated systolic 
hypertension does not appear in Figure 1 but is deﬁ  ned in the 
Guidelines as  140 (systolic) and  90 (diastolic).
Total cardiovascular risk
The 2007 Guidelines emphasize that diagnosis and manage-
ment of hypertension should be related to quantiﬁ  cation of 
total (or global) CV risk, usually expressed as the absolute 
risk of having a CV event within 10 years. This more holistic 
approach recognizes that the majority of patients with high 
BP exhibit additional CV risk factors, and the potentiation 
of concomitant BP and metabolic risk factors leads to a CV 
risk that is more than the sum of the individual components 
(Multiple Risk Factor Intervention Trial Research Group 
1986; Assmann and Schulte 1988; Wei et al 1996; Kannel 
et al 2000; Thomas et al 2001; Asia Paciﬁ  c Cohort Studies 
Collaboration 2005; Mancia et al 2006a). The total CV risk 
should be used to grade intensity of therapeutic approach and 
guide decisions on treatment strategies, including:
•  Initiation of drug treatment
•  BP threshold and target
•  Use of combination treatment or additional non-
antihypertensive agents
•  Cost-effectiveness.
The Guidelines summarize factors inﬂ  uencing prognosis 
and risk classiﬁ  cation (see Box 1 and Table 1), yet it is acknowl-
edged that there are limitations to the application of standard-
ized CV risk models in a real-world setting, and also intrinsic 
conceptual limitations associated with the rationale of estimat-
ing total risk as a way to best assign limited resources.
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Figure 1 Stratiﬁ  cation of CV risk into four categories.
Low, moderate, high and very high risk refer to 10-year risk of a CV fatal or non-fatal event. The term ‘‘added’’ indicates that in all categories risk is greater than average. 
The dashed line indicates how deﬁ  nition of hypertension may be variable, depending on the level of total CV risk.
Abbreviations: DBP, diastolic blood pressure; CV, cardiovascular; HT, hypertension; MS, metabolic syndrome; OD, subclinical organ damage; SBP, systolic blood pressure.Vascular Health and Risk Management 2007:3(6) 785
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Diagnosis
The aim of diagnostic procedures is to establish BP levels, 
identify secondary causes of hypertension and evaluate the 
overall CV risk through assessment of risk factors, target 
organ damage and concomitant disease or accompanying 
clinical conditions.
Measurement
BP measurements are most accurate when an average is taken 
of multiple reads recorded over at least 2–3 visits. However, 
in severe cases, diagnosis can be based on one measurement 
alone. Practical considerations when measuring BP in the 
clinical setting are summarized in Box 2.
Recent studies form a growing body of evidence to 
suggest that out-of-ofﬁ  ce BP readings are more closely cor-
related to severity of hypertension than those taken in the 
clinical setting and, as such, are a more accurate predictor of 
true CV risk (Khattar et al 1998; Fagard et al 2000; Bobrie 
2004; Fagard and Celis 2004; Fagard et al 2005a; Ohkubo 
et al 2005; Verdecchia et al 2005; Hansen et al 2006; Mancia 
et al 2006b). The Guidelines’ recommendations regarding 
self-measurement of BP at home include:
•  Use of validated and semiautomatic devices for simplicity 
and accuracy
•  Taking measurements while in the sitting position (after 
several minutes of rest) and keeping the arm at heart level 
during measurement with wrist devices
•  Measurement of BP in the morning and in the evening, 
and both pre- and post-treatment to monitor the effect of 
drug intake.
The Guidelines also advise that it is prudent to educate 
patients about spontaneous changes in BP that may result 
in ﬂ  uctuating readings. Clinicians are also reminded of the 
phenomenon of isolated ofﬁ  ce (or clinic) hypertension, ie, 
130–135/85 mmHg as measured at home approximately 
corresponds to 140/90 mmHg.
Physical examination and laboratory 
investigations
In addition to BP measurements, heart rate, body mass index 
(BMI) and waist circumference should be carefully recorded. 
Physical examination should also search for evidence of 
additional risk factors, signs of secondary hypertension or 
evidence of organ damage, eg, palpation of enlarged kidneys, 
ausculation of abdominal murmurs or of precordial or chest 
murmurs, features of Cushing Syndrome, or diminished and 
delayed femoral pulses and reduced femoral BP.
Laboratory examinations can provide evidence of additional 
risk factors. Routine laboratory investigations should include 
blood chemistry for fasting glucose; total cholesterol, low-
density lipoprotein (LDL) cholesterol and high-density lipopro-
tein (HDL) cholesterol; triglycerides (fasting); urate; creatinine; 
potassium, hemaglobin and hematocrit, urinalysis by a dipstick 
test and electrocardiogram. Further tests are recommended and 
include home and ambulatory BP monitoring, ankle-brachial 
index (ABI), echocardiogram, fundoscopy, glucose tolerance 
test, pulse wave velocity measurement, quantitative proteinuria 
and carotid ultrasound. The younger the patient, the higher the 
BP and the faster the development of their hypertension, the 
more thorough the diagnostic assessment should be.
Family and clinical history
There is often a family history of high BP in hypertensive 
patients, suggesting that inheritance contributes to the 
pathogenesis of the disorder. A comprehensive family his-
tory should be taken, with particular attention being paid to 
hypertension, diabetes, dyslipidemia, premature coronary 
heart disease, stroke, PAD and renal disease. The clinical 
history should include:
•  Past history and duration of previous levels of high BP 
and subsequent antihypertensive treatment
•  Symptoms suggestive of secondary causes of hypertension
•  Lifestyle factors (eg, physical activity level, diet, smoking 
and alcohol consumption) and past or current symptoms 
of coronary disease, heart failure, cerebrovascular or 
peripheral vascular disease (PVD), renal disease, diabetes 
mellitus, gout, dyslipidemia, asthma or other signiﬁ  cant 
illnesses and related medication prescribed.
Subclinical organ damage
There is a large body of evidence available on the crucial role 
of subclinical organ damage in determining the CV risk of 
Box 1 High/very high-risk subjects
ο BP    180 mmHg systolic and/or   110 mmHg diastolic
ο Systolic  BP   160 mmHg with low diastolic BP ( 70 mmHg)
ο Diabetes  mellitus
ο Metabolic  syndrome
ο  Three CV risk factors
ο  One or more of the following subclinical organ damages:
 –    Electrocardiographic (particularly with strain) or echocardio-
graphic (particularly concentric) left ventricular hypertrophy
 –    Ultrasound evidence of carotid artery wall thickening or plaque
  –  Increased arterial stiffness
  –  Moderate increase in serum creatinine
 –    Reduced estimated glomerular ﬁ  ltration rate or creatinine clearance
  –  Microalbuminuria or proteinuria
ο  Established CV or renal diseaseVascular Health and Risk Management 2007:3(6) 786
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individuals with and without high BP. In recognition of the 
importance of subclinical organ damage as an intermediate 
stage in the continuum of vascular disease and as an indicator 
of total CV risk, the Guidelines devote a section to the discus-
sion of the evidence for the risk represented by various organ 
abnormalities and methods for their detection (see Table 2). 
It is important to note that arterial assessments, as evaluated 
by arterial stiffness, carotid-femoral pulse wave velocity, 
ankle-brachial BP index and carotid wall thickness, now 
ﬁ  gure prominently in the list of sub-clinical organ damage.
Treatment strategies
Non-pharmacological interventions
Positive lifestyle changes should be instituted in both patients 
with hypertension and in those with normal-high BP and 
additional risk factors. Lifestyle interventions should be im-
plemented, irrespective of whether pharmacological therapy 
is prescribed, to lower BP and to help control other risk 
Table 1 Factors inﬂ  uencing prognosis
Risk factors Subclinical organ damage
  Systolic and diastolic BP levels
  Levels of pulse pressure (in the elderly)
  Age (M >55 years; W >65 years)
  Smoking
  Dyslipidemia
   – TC   5.0 mmol/L (190 mg/dL) or; 
   – LDL-C   3.0 mmol/L (115 mg/dL) or; 
   – HDL-C: M   1.0 mmol/L (40 mg/dL), 
   W   1.2 mmol/L (46 mg/dL), or; 
   – TG   1.7 mmol/L (150 mg/dL) or
  Fasting plasma glucose 5.6–6.9 mmol/L (102–125 mg/dL)
  Abnormal glucose tolerance test
    Abdominal obesity (waist circumference  102 cm (M),  88 cm 
(W))
    Family history of premature CV disease (M at age  55 years; 
W at age  65 years)
  Electrocardiographic LVH (Sokolow-Lyon >38 mm; Cornell >2440 mm*ms) or
  Echocardiographic LVHa (LVMI M   125 g/m2, W   110 g/m2)
  Carotid wall thickening (IMT   0.9 mm) or plaque
  Carotid-femoral pulse wave velocity  12 m/s
  Ankle/brachial BP index  0.9
  Slight increase in plasma creatinine:
   M:  115–133  μmol/L (1.3–1.5 mg/dL)
   W:  107–124  μmol/L (1.2–1.4 mg/dL)
    Low estimated glomerular ﬁ  ltration rateb ( 60 mL/mn/1.73 m2) or creatine 
clearancec ( 60 mL/min)
    Microalbuminuria 30–300 mg/24 hr or albumin-creatinine ratio:  22(M); or 
 31(W) mg/g creatinine
Diabetes mellitus Established CV or renal disease
    Fasting plasma glucose  7.0 mmol/L (126 mg/dl) on repeated 
measurement, or
  Postload plasma glucose  11.0 mmol/L (198 mg/dL)
    Cerebrovascular disease: ischemic stroke; cerebral hemorrhage; transient 
ischemic attack
    Heart disease: myocardial infarction; angina; coronary revascularization; heart 
failure
    Renal disease: diabetic nephropathy; renal impairment (Serum creatinine 
M   133 mmol/L, W   124 mmol/L); proteinuria ( 300 mg/24 hr)
  Peripheral arterial disease
  Advanced retinopathy: hemorrhages or exudates, papilloedema
aRisk maximal for concentric LVH (left ventricular hypertrophy): increased LVMI (left ventricular mass index) with a wall thickness/radius ratio ≥0.42; bMDRD formula; 
cCockroft Gault formula.
Abbreviations: BP, blood pressure; C, cholesterol; CV, cardiovascular disease; IMT, intima-media thickness; M, men; W, women; TG, triglycerides.
Note: the cluster of three out of 5 risk factors among abdominal obesity, altered fasting plasma glucose, BP   130/85 mmHg, low HDL-cholesterol and high TG (as deﬁ  ned 
above) indicates the presence of metabolic syndrome.
Box 2 Guidance for correct ofﬁ  ce blood pressure 
measurements
Blood pressure (BP) measurement
When measuring BP, care should be taken to:
•   Allow the patients to sit for several minutes in a quiet room before 
beginning BP measurements
•   Take at least two measurements spaced by 1–2 minutes, and addi-
tional measurements if the ﬁ  rst two are quite different
•   Use a standard bladder (12–13 cm long and 35 cm wide) but have a 
larger and a smaller bladder available for fat and thin arms, respec-
tively. Use the smaller bladder in children
•  Have the cuff at the heart level, whatever the position of the patient
•   Use phase I and V (disappearance) Korotkoff sounds to identify sys-
tolic and diastolic BP, respectively
•   Measure BP in both arms at ﬁ  rst visit to detect possible differences 
due to peripheral vascular disease. In this instance, take the higher 
value as the reference one
•   Measure BP 1 and 5 min after assumption of the standing position in 
elderly subjects, diabetic patients, and in other conditions in which 
postural hypotension may be frequent or suspected
•   Measure heart rate by pulse palpation (at least 30 sec) after the 
second measurement in the sitting position
Note: the cluster of three out of 5 risk factors among 
abdominal obesity, altered fasting plasma glucose, BP ≥130/85 
mmHg, low HDL-cholesterol and high TG (as deﬁ  ned above) 
indicates the presence of metabolic syndromeVascular Health and Risk Management 2007:3(6) 787
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factors and clinical conditions. In so doing, the subsequent 
antihypertensive pill burden for patients may be reduced and 
the associated economic consequences minimized.
Effectiveness of lifestyle measures can vary and long-
term compliance is low (Haynes et al 2002). In order to 
optimize outcomes, interventions should be introduced 
alongside adequate behavioral and expert support, and 
reinforced periodically. In light of poor adherence in the 
long term, patients under non-pharmacological treatment 
should receive close follow-up to ensure that drug therapy 
is initiated when required. Appropriate lifestyle interven-
tions include: smoking cessation, moderation of alcohol 
consumption, increased physical activity, sodium restric-
tion and advice on weight management and healthy eating 
(Dickinson et al 2006).
Smoking cessation
Smoking is a powerful CV risk factor (Doll et al 1994) and 
cessation may be the single most effective lifestyle meas-
ure for the prevention of a large number of CV diseases, 
including stroke and myocardial infarction (MI) (Rosenberg 
et al 1985; Manson et al 1992; Doll et al 1994). Nicotine 
replacement therapy (Silagy et al 1994), bupropion therapy 
(Tonstad et al 2003) or varenicline (Nides et al 2006) should 
be considered to facilitate smoking cessation.
Moderation of alcohol consumption
The relationship between alcohol consumption, BP levels 
and the prevalence of hypertension is linear (Puddey et al 
1994), and high consumption is related to a high risk of 
stroke (Wannamethee and Shaper 1996). Trials investigating 
Table 2 Methods of subclinical organ damage detection
Area of assessment Detection methods
Heart Electrocardiography (should be routine in patients with high BP):
•  left ventricular (LV) hypertrophy
•  patterns of strain
• ischemia
• arrhythmias
•  geometric patterns – concentric hypertrophy carries the worse prognosis
Echocardiography is recommended when a more sensitive detection of LV hypertrophy is consid-
ered useful
Transmitral Doppler: diastolic dysfunction
Brain Magnetic resonance imaging (MRI) or CAT (CT):
•  silent brain infarcts
• lacunar  infarctions
• microbleeds
•  white matter lesions
Availability and costs do not allow indiscriminate use of these techniques
Cognitive tests
•  initial brain deterioration in elderly patients with hypertension
Kidney Serum creatinine of glomerular ﬁ  ltration rate or creatinine clearance (should be routine for patients 
with hypertension):
•  hypertension-related renal damage – based on reduced renal function or Dipstick:
•   urinary protein – dipstick negative patients low-grade albuminuria (microalbuminuria) should 
be determined in spot urine and related to urinary creatinine excretion
Blood vessels Ultrasound scanning of carotid arteries:
• vascular  hypertrophy
•  asymptomatic atherosclerosis is deemed useful
Pulse wave velocity:
•  large artery stiffening (leading to isolated systolic hypertension in the elderly)
Ankle-brachial index:
•  peripheral arterial disease (PAD) – advanced PAD signaled by low index
Eye Fundoscopy (recommended in severe hypertension only):
• hemorrhages
• exudates
• papilloedema
Mild retinal changes are largely non-speciﬁ  c except in young patientsVascular Health and Risk Management 2007:3(6) 788
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alcohol reduction have shown a signiﬁ  cant drop in systolic 
and diastolic BPs (Dickson et al 2006). The Guidelines 
recommend a daily intake of  20–30 g ethanol/day for 
male patients with hypertension and 10–20 g ethanol/day 
for female patients. All patients with hypertension are also 
recommended to avoid binge drinking.
Physical activity
Lack of physical ﬁ  tness is strongly correlated with CV mor-
tality, independent of BP and other risk factors (Sandvick 
et al 1993). Even moderate levels of exercise can lower BP 
(Fagard 2001), reduce body weight, fat, waist circumference, 
increase insulin sensitivity and HDL-cholesterol levels. Sed-
entary patients are recommended to undertake 30–45 minutes 
of moderate intensity, primarily endurance, activity daily (eg, 
walking, jogging, swimming). This can then be supplemented 
with resistance exercise (Jennings 1997; Stringer et al 2005). 
In patients in whom hypertension is poorly controlled, how-
ever, the Guidelines warn that heavy physical exercise and 
maximal exercise testing should be discouraged or postponed 
until appropriate drug treatment has been instituted and BP 
lowered (Fagard et al 2005b).
Sodium restriction
Epidemiological studies suggest that dietary salt intake 
is a contributor to BP elevation and to the prevalence of 
hypertension (Law 1997; WHO/FAO 2003). The beneﬁ  t of 
sodium restriction is greater in blacks, middle-aged and older 
patients, as well as in individuals with hypertension, diabe-
tes or chronic kidney disease. Ideal daily intake of sodium 
chloride is targeted at 3.8 g, although it is recognized that a 
target of  5 g may be more realistic and achievable.
Weight management and healthy 
eating
Weight loss should be encouraged in overweight patients; 
support and counselling from trained dieticians may be 
beneﬁ  cial. Healthy eating should be promoted because of its 
BP-lowering effects (Sacks et al 2001): increased fruit and 
vegetable intake (4–5 servings, or 300 g/day) and a reduction 
in saturated and total fat intake.
Pharmacological interventions
The primary goal of treatment in patients with hypertension is to 
achieve maximum reduction in the long-term total risk of CVD. 
This requires the treatment of both raised BP and all associated 
reversible risk factors. BP targets are (systolic/diastolic):
•   140/90 mmHg in all patients with hypertension
•   130/80 mmHg in patients with diabetes and in high-
risk, or very high-risk, patients (eg, those with associated 
clinical conditions such as stroke, MI, renal dysfunction, 
proteinuria).
It may be difﬁ  cult to achieve BP targets, especially in 
elderly and diabetic patients, and in patients with CV dam-
age. It is recommended that antihypertensive treatment be 
initiated before signiﬁ  cant CV damage develops to maximize 
the probability of achieving target BP.
Treatment options
There are ﬁ  ve major classes of such agents licensed for 
initiation or maintenance of hypertension, alone or in com-
bination: thiazide diuretics; calcium antagonists (CA); ACE 
inhibitors (ACEI); agiotensin receptor antagonists (ARB), 
and β-blockers (BB). The choice of a speciﬁ  c drug or com-
bination should take into account the following:
ο  Previous patient exposure to, and history with, a class of 
compounds
ο  CV risk associated with agent and the patient’s CV risk 
proﬁ  le
ο  Presence of other disorders and conditions (see Table 3)
ο  Possible drug interactions
ο  Cost considerations (although these should not predomi-
nate over efﬁ  cacy, tolerability and patient protection)
ο  Side-effects and their potential impact on compliance
ο  Duration of antihypertensive effect – once-daily administra-
tion should be preferred because of correlations between 
simplicity of treatment regimen and improved compliance.
Monotherapy
Where possible, treatments should be initiated as low-dose 
monotherapy. Where the initiating dose of the original agent 
proves ineffective, it can be increased to its maximum or 
an alternate agent from a different class can be prescribed. 
This sequential monotherapy approach is recommended in 
uncomplicated hypertensives and in the elderly, and can help 
establish to which agent the patient responds best. However, it 
can be laborious and can lead to low compliance and delayed 
control of BP in patients with high-risk hypertension.
Combination therapy
Although it is possible to achieve target BP ( 140/90 mmHg) 
in some patients through lifestyle interventions and mono-
therapy, the majority of patients (70%–80%) require the use 
of more than one agent (Dickerson et al 1999; Morgan et al 
2001). Antihypertensive agents can be combined if they 
have different and complementary mechanisms of action and Vascular Health and Risk Management 2007:3(6) 789
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where their combined use either offers greater efﬁ  cacy than 
that of either of the combination components, or a favorable 
tolerability proﬁ  le, or both.
The Guidelines recommend consideration of combination 
treatment as ﬁ  rst choice, particularly when there is a high CV 
risk, to avoid delay in treatment of high BP in high-risk individu-
als. Use of combination therapy at treatment initiation also offers 
the beneﬁ  t of prescribing both agents at their lowest dose. This 
should result in a minimization of potential side-effects and im-
prove related compliance, especially as ﬁ  xed-dose combinations 
offer dual administration via one tablet, retaining the simplicity 
of the treatment regimen. The following two-drug combinations 
have been found to be effective and well tolerated, and have 
been favorably used in randomized efﬁ  cacy trials:
Table 3 Guideline’s recommendations on preferred drug classes for various conditions and those conditions for which there is 
compelling evidence, or evidence suggestive, of contraindication to use of a class of agents
Drug Class Conditions favoring use Compelling contraindications Possible contraindications
Thiazide diuretics isolated systolic hypertension (elderly) gout metabolic syndrome
heart failure   glucose intolerance
hypertension in blacks   pregnancy
Diuretics (antialdosterone) heart failure renal failure  
post-MI hyperkalemia  
Loop diuretics end stage renal disease    
heart failure    
Beta blockers angina pectoris asthma peripheral arterial disease
post-MI A-V block (grade 2 or 3) metabolic syndrome
heart failure   glucose intolerance
tachyarrhythmias
glaucoma
pregnancy
 
athletes and physically active 
patients
chronic obstructive pulmonary 
disease
Calcium antagonists
(dihydropyridines)
isolated systolic hypertension (elderly)   tachyarrhythmias
angina pectoris heart failure
LV hypertrophy    
carotid/coronary atherosclerosis    
pregnancy   
hypertension in blacks    
Calcium antagonists
(verapamil, diltiazem)
angina pectoris A-V block (grade 2 or 3)  
carotid atherosclerosis heart failure  
supravenricular tachycardia    
ACE inhibitors heart failure pregnancy  
LV dysfunction angioneurotic edema  
post-MI hyperkalemia  
diabetic nephropathy bilateral renal artery stenosis  
LV hypertrophy    
carotid atherosclerosis    
proteinuria/mircroalbuminuria   
atrial ﬁ  brillation    
metabolic syndrome    
Angiotensin receptor 
antagonists
heart failure pregnancy  
post-MI hyperkalemia  
diabetic nephropathy bilateral renal artery stenosis  
proteinuria/mircroalbuminuria   
LV hypertrophy    
atrial ﬁ  brillation    
metabolic syndrome    
ACEI-induced cough    
Abbreviations: ACEI, ACE inhibitors; LV, Left ventricle; MI, myocardial infarction.Vascular Health and Risk Management 2007:3(6) 790
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ο  Thiazide diuretic and ACEI
ο  Thiazide diuretic and ARB
ο  Thiazide diuretic and BB (although this should be avoided 
in patients with metabolic syndrome or high risk of inci-
dent diabetes because of dysmetabolic effects)
ο  CA and ACEI
ο  CA and ARB
ο  CA and thiazide diuretic
ο  BB and CA (dihydropiridine)
When it is not possible to achieve BP control through lifestyle 
interventions and the use of two drugs, a combination of three 
agents should be tried. If systolic and diastolic BP goals fail 
despite treatment, including a therapeutic plan, lifestyle mea-
sures and the prescription of a diuretic and at least two other 
drugs, the patient may have resistant hypertension. Table 4 
lists some of the main causes of resistant hypertension. The 
ﬁ  rst management step is a careful elicitation of the history, 
followed by a thorough examination to exclude secondary 
causes of hypertension. It is also crucial to assess whether 
compliance is adequate. Ultimately, many patients will need 
administration of more than three drugs, but the optimal 
choice of third, fourth and ﬁ  fth-line antihypertensive agents 
has not been properly addressed by RCTs.
Therapeutic approach
All patients whose repeated BP measurements show 
grade 2 or 3 hypertension are definite candidates for 
antihypertensive treatment. The body of evidence for the 
beneﬁ  t of treating grade 1 hypertension is less robust as speciﬁ  c 
trials have not addressed the issue. The Guidelines support 
consideration of antihypertensive interventions when systolic 
BP is  140 mmHg. 
Speciﬁ  c patient groups
It is acknowledged that Guidelines deal with a disease, while 
physicians deal with patients. Every patient has speciﬁ  c needs 
and particularities for which treatment is individualized to 
achieve maximum therapeutic effect. With a view to offering 
guidance on appropriate targets and treatment in less standard 
situations, the Guidelines discuss therapeutic approaches in 
special conditions.
Elderly patients
RCTs have shown that older patients ( 60 years) beneﬁ  t from 
antihypertensive drug treatment in terms of reduced CV morbid-
ity and mortality (Collins and MacMahon 1994; Staessen et al 
2000). As a result, a treatment goal of BP   140/90 mmHg is 
recommended in elderly patients with hypertension. However, 
it is conceded that achievement of this target may be difﬁ  cult in 
the elderly and is likely to require combination therapy.
The Guidelines advise that treatment should proceed in 
line with general guidelines and with full consideration of risk 
factors, but that the initial dose used, and subsequent titration, 
should be more gradual to minimize adverse events. It is also of 
note that, as there is an increased risk of postural hypotension in 
elderly patients, BP measurements should be undertaken with 
patients in the erect posture. If well tolerated, continuation of 
antihypertensive regimen post 80 years is recommended, but 
initiation in patients  80 remains unproven.
Diabetes
The coexistence of hypertension and either type 1 or type 
2 diabetes substantially increases risk of developing renal 
and other organ damage, leading to increased incidence of 
stroke, CHD, congestive heart failure, PAD and CV mortal-
ity (Stamler et al 1993). For this reason a strict treatment BP 
target of  130/80 mmHg is recommended in patients with 
either form of diabetes.
Lifestyle interventions (especially caloric intake and in-
creased physical activity) are also strongly encouraged, as is 
the initiation of pharmacological approaches when BP is in the 
high-normal range. The Guidelines suggest that a treatment 
regimen including an ARB or ACEI may afford antiproteinuric 
effects and additional protection on appearance and progression 
of renal damage. Where monotherapy is appropriate, an ARB 
or ACEI is recommended and should be included in combina-
tion regimens, which are frequently required. As in the case 
of elderly patients, an increased risk of postural hypotension 
Table 4 Common causes of resistant hypertension
ο  Poor adherence to therapeutic plan
ο  Failure to modify lifestyle including:
   ο  weight  gain
   ο   heavy alcohol intake (NB: binge drinking)
ο   Continued intake of drugs that raise blood pressure (eg, liquorice, 
cocaine, glucocorticoids, non-steroid anti-inﬂ  ammatory drugs)
ο  Obstructive sleep apnea
ο  Unsuspected secondary cause
ο  Irreversible or scarcely reversible organ damage
ο  Volume overload due to:
   ο   inadequate diuretic therapy
   ο   progressive renal insufﬁ  ciency
   ο   high sodium intake
   ο  hyperaldosteronism
Causes of spurious resistant hypertension:
ο Isolated  ofﬁ  ce (white-coat) hypertension
ο  Failure to use large cuff on large arm
ο PseudohypertensionVascular Health and Risk Management 2007:3(6) 791
EDITORIAL
in patients with diabetes leads to the advice that BP should be 
measured while patients are in the erect posture.
Cerebrovascular disease
Antihypertensive treatment markedly reduces the incidence 
of recurrent stroke and lowers the associated risk of cardiac 
events in patients with a history of stroke or TIA (PROGRESS 
Collaborative Study Group 2001; PATS Collaborative Group 
1995). For patients with cerebrovascular disease, a treatment 
goal of BP  130/80 mmHg is recommended and pharma-
cological interventions should be initiated when BP is in the 
high-normal range.
Evidence suggests the beneﬁ  t of antihypertension in this patient 
group is afforded by BP reduction (PROGRESS Collaborative 
Study Group 2001; Arima et al 2006). The Guidelines therefore 
advise the use of all available drugs and rational combinations 
in order to reach target BP. Observational studies also indicate a 
correlation between BP value and cognitive decline and incidence 
of dementia, which may be delayed by antihypertensive treatment 
(Launer et al 1995; Skoog et al 1996; Kilander et al 1998). Data 
are currently lacking in acute stroke, but initiation of treatment is 
advised when post-stroke clinical conditions are stable.
Coronary heart disease and heart 
failure
Patients with coronary heart disease (CHD) often have a 
history of hypertension and the risk of a fatal or non-fatal 
coronary event post MI is greater if BP is elevated (Domanski 
et al 1999; Yap et al 2007). The Guidelines recommend post-
MI administration of BB, ACEI or ARBs, which have been 
shown to reduce the incidence of recurrent MI and death 
largely because of direct organ protective properties of the 
agents, but may be supported by the associated reduction in 
BP as a result of these agents (Freemantle et al 1999; Dickstein 
et al 2002; Pfeffer et al 2003; Shekelle et al 2003; Lee et al 
2004). The beneﬁ  t of BP control is also true for patients with 
chronic CHD. Raised BP is relatively rare in patients with con-
gestive heart failure; treatment in these patients can include 
thiazide and loop diuretics, BBs, ACEIs and ARBs, but the 
Guidelines warn against the use of a CA in these patients, 
unless needed to control BP or anginal symptoms.
Atrial ﬁ  brillation
Hypertension is the most important risk factor for atrial 
ﬁ  brillation (AF) on a population basis (Kannel et al 1998). 
The Guidelines recommend the beneﬁ  t of blockade of the 
renin-angiotensin system by either an ACEI or ARB in patients 
with paroxysmal AF and congestive heart failure. In permanent 
AF, BB and non-dihydropiridine CA remain important classes 
of drugs for the control of ventricular rate.
Women
Both genders respond to antihypertensive agents and beneﬁ  t 
from the effects of lowering BP, but there are additional con-
siderations that should be taken into account when prescribing 
for women. If women are pregnant, or planning a pregnancy, 
the Guidelines advise avoidance of potentially teratogenic 
drugs (ie, ACEIs and ARBs). Other female-speciﬁ  c points of 
note made in the Guidelines are: that oral contraception causes 
mild BP elevation – the progestogen-only pill is an option in 
women shown to have high BP; that hormone replacement 
therapy is not currently recommended for cardio protection 
in postmenopausal women because of its associated adverse 
events, and the potential adverse effects of hypertension on 
neonatal and maternal outcomes. The Guidelines make the 
following recommendation for pregnant women:
ο  Systolic BP 140–149 mmHg or diastolic BP 90–95 
mmHg: non-pharmacological management, including 
supervision and restriction of activities
ο  BP  140/90 mmHg (with or without proteinuria): drug 
treatment is indicated
ο  Systolic BP  170 mmHg or diastolic BP  110 mmHg: 
emergency hospitalization
ο  Non-severe hypertension: oral methyldopa, lebetalol, CA 
or possibly BB
ο  Pre-eclampsia with pulmonary edema: nitroglycerine is 
the drug of choice; diuretic therapy is inappropriate.
Intravenous labetalol, oral methyldopa and oral nifedipine 
are indicated for emergency treatment. Calcium supplemen-
tation, ﬁ  sh oil and low-dose aspirin are not recommended, 
although low-dose aspirin may be used prophylactically in 
women with a history of early onset pre-eclampsia.
Metabolic syndrome
The metabolic syndrome is characterized by the variable combi-
nation of visceral obesity and alterations in glucose metabolism, 
lipid metabolism and BP. It is most prevalent in middle-aged 
and elderly populations and confers signiﬁ  cant increased risk of 
CV morbidity and mortality, developing diabetes, organ dam-
age and new onset hypertension (Vasan et al 2001a, b; Lakka 
et al 2002; Vasan et al 2002; Dunder et al 2003; Resnick et al 
2003; Girman et al 2004; Dekker et al 2005; Mule et al 2005; 
Schmidt et al 2005; Mancia et al 2007a).
The Guidelines recommend implementation of lifestyle 
interventions, including weight loss of 7%–10% over 6–12 
months, as the ﬁ  rst and main treatment strategy (Mancia et al Vascular Health and Risk Management 2007:3(6) 792
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2007b). In patients with metabolic syndrome, a more in-depth 
assessment of subclinical organ damage is recommended, as 
is measurement of ambulatory and home BP.
Where there is hypertension, or possibly high-normal BP, 
it is advised to initiate treatment with a blocker of the renin-
angiotensin system to minimize the facilitation of diabetes 
onset potentially conferred by other agents. If necessary, a 
CA or a low-dose thiazide diuretic may be used in combi-
nation. Statins should also be prescribed in the presence of 
dyslipidemia, and antidiabetic drugs for diabetes.
Secondary hypertension
A secondary form of hypertension is suggested by a severe 
BP elevation, sudden onset or worsening of hypertension 
and BP responding poorly to drug therapy. Simple screening 
for secondary forms of hypertension can be obtained from 
clinical history, physical examination and routine laboratory 
investigations. The Guidelines outline speciﬁ  c diagnostic 
procedures for the following conditions:
•  Renal parenchymal disease
•  Renovascular hypertension
•  Pheochromocytoma
•  Primary aldosteronism
•  Cushing’s syndrome
•  Obstructive sleep apnea
•  Coarctation of the aorta
•  Drug-induced hypertension
Hypertension emergencies
Severe forms of high BP are associated with acute damage 
to target organs, resulting in hypertensive emergencies. 
They tend to be rare, but are life threatening and should be 
treated promptly in the same way as chronic BP elevations, 
although caution should be taken in the rapid reduction of BP 
in patients with acute stroke. The most important hyperten-
sion emergencies are listed in Table 5.
Associated risk factors
The Guidelines also offer recommendations for the pharma-
cological treatment of associated risk factors, covering lipid-
lowering agents, antiplatelet therapy and glycemic control.
Lipid lowering agents
Statin therapy should be considered in all patients with 
hypertension and established CVD or with type 2 diabetes. 
Total serum targets of  4.5 mmol/L (175 mg/dL) and LDL 
cholesterol levels of  2.5 mmol/L (100 mg/dL) are recom-
mended. A statin should also be considered in patients with 
hypertension without overt CVD but with high CV risk 
( 20% risk of events in 10 years), even if their baseline total 
and LDL serum cholesterol levels are not elevated.
Antiplatelet therapy
Antiplatelet therapy, in particular low-dose aspirin, should be 
prescribed to patients with hypertension and a history of CV 
events, provided that there is no excessive risk of bleeding. 
Low-dose aspirin should also be considered in patients with 
hypertension who are  50 years old, even in those without 
a history of CVD, if they have a moderate increase in serum 
creatinine or high CV risk. In all these conditions, the ben-
eﬁ  t-to-risk ratio (weighed as a reduction of MI risk against 
bleeding) has been proven favorable. To minimize the risk of 
hemorrhagic stroke, antiplatelet treatment should be initiated 
only when effective BP control has been achieved.
Glycemic control
Diabetes and impaired glucose tolerance are major risk 
factors for CVD (Stamler et al 1993; Knowler et al 1997; 
Haffner et al 1998), making effective glycemic control of 
great importance in patients with hypertension and diabetes. 
In these patients dietary and drug treatment of diabetes should 
aim at lowering plasma fasting glucose to values  6 mmol/l 
(108 mg/dl) and at a glycated hemoglobin of  6.5%.
Compliance
Treatment of hypertension should be continued for life as 
cessation in correctly diagnosed patients is associated with 
a return to the hypertensive state. However, cautious down-
ward titration of established treatment may be attempted in 
low-risk patients after long-term BP control, particularly if 
non-pharmacological treatment can be successfully imple-
mented and if it is associated with home monitoring.
Educating patients of the risk of hypertension and the 
beneﬁ  t of treatment can help improve compliance. Clear 
written and oral instructions on disease and treatment plans 
should be offered to the patient and their family. Simplifying 
the treatment regimen (eg, use of a once-daily medication) 
and tailoring it to the patient’s lifestyle can also improve 
compliance. Retaining open channels of communication with 
the patient, regarding side-effects, their potential problems 
with adherence and offering reliable support and affordable 
prices can also be beneﬁ  cial.
Patient follow-up
Patients on non-pharmacological interventions require 
frequent follow-up visits to maximize compliance, to rein-Vascular Health and Risk Management 2007:3(6) 793
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force the treatment approach and to monitor BP, allowing a 
prompt and timely switch to pharmacological interventions 
if necessary.
During the titration phase of pharmacological therapy, 
patients should receive regular checkups (eg, every 2–4 
weeks) in order to optimize the treatment regimen – drug 
dose and/or combination – to maximize effectiveness and 
minimize adverse events. The Guidelines advise an added 
beneﬁ  t of instructing patients to self-measure BP at home 
during this phase.
Frequency of visits can be reduced considerably once 
target BP and other treatment goals have been achieved, eg, 
every 6 months for patients with low additional CV risks, 
but more frequently where there are concomitant risk factors. 
However, the Guidelines underline several beneﬁ  ts of ensur-
ing regularity and frequency of follow-up visits, including 
the reinforcement of a strong doctor-patient relationship 
(crucial to treatment effectiveness and compliance) and the 
opportunity to monitor all reversible risk factors and assess 
target organ damage (LV mass and carotid artery wall thick-
ness are slow, so a maximum once-yearly examinations are 
recommended).
Cost-effectiveness
Several studies have shown that in high- and very high-
risk patients, treatment of hypertension is largely cost-
effective – the reduction in the incidence of CVD and death 
largely offsets the cost of treatment despite its lifetime 
duration (Ambrosioni 2001). Early initiation of treatment is 
crucial and primarily aims to prevent onset and/or progres-
sion of organ damage that would result in low-risk patients 
progressing to the high-risk category over time. Several 
trials of antihypertensive have suggested that some of the 
major CV risk changes may be difﬁ  cult to reverse, and that 
restricting antihypertensive therapy to patients at high or 
very high risk may be far from an optimal strategy (Hansson 
et al 1998; Zanchetti et al 2001). Another observation made 
in the Guidelines is that the cost of hypertensive drug treat-
ment is often contrasted with lifestyle measures, which are 
considered to be cost-free. However, this can be mislead-
ing as real implementation, and therefore effectiveness, of 
lifestyle changes requires behavioral support, counseling 
and reinforcement.
Implementation
The Guidelines conclude with the recognition that there are 
numerous barriers between recommendations and their adop-
tion in practice. One important obstacle can be the consider-
ation by physicians that guidelines deal with the disease while 
the practice of medicine deals with the individual patient. In 
view of this, the Guidelines were prepared in such a way as to 
make them widely informative and minimally prescriptive.
True implementation of the Guidelines requires realiza-
tion of their full potential by relevant medical professionals. 
The Guidelines should be interpreted at a national level to 
reﬂ  ect local healthcare organization, cultural background 
and socioeconomic situations.
Health providers may wrongly assume that the manage-
ment of hypertension can be easily addressed in a just a few, 
brief visits, and can be tempted to reimburse accordingly. 
Policy-makers should develop comprehensive prevention 
programs that will guarantee full reimbursement and eradi-
cate the view of guidelines as a means to reducing cost – a 
misconception that can lead to reimbursement being limited 
to high-risk conditions deﬁ  ned by arbitrary cutoffs.
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